New pill shows promise for Tough-to-Treat lymphoma
NCT ID NCT03593018
First seen Apr 26, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This study tested an oral chemotherapy drug (azacitidine) against standard single-drug treatments for people with a rare type of blood cancer called angioimmunoblastic T-cell lymphoma that had returned or not responded to prior therapy. The goal was to see if the new pill could delay cancer growth better than usual options. 86 adults took part, and researchers measured how long patients lived without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A. Z. Sint-Jan Brugge-Oostende AV
Bruges, Belgium
-
Aarhus University Hospital
Aarhus, Denmark
-
CH Annecy Genevois
Pringy, France
-
CHRU de Lille
Lille, France
-
CHRU de Nancy - Hôpital de Brabois
Vandœuvre-lès-Nancy, France
-
CHU Haut-Lévèque - Centre François Magendie
Pessac, France
-
CHU Henri Mondor
Créteil, France
-
CHU Lyon-Sud
Pierre-Bénite, France
-
CHU Pontchaillou
Rennes, France
-
CHU UCL Namur - Site Godinne
Yvoir, Belgium
-
CHU de Clermont-Ferrand - Hôpital Estaing
Clermont-Ferrand, France
-
CHU de Dijon
Dijon, France
-
CHU de Grenoble
Grenoble, France
-
CHU de Montpellier - Hôpital Saint-Eloi
Montpellier, France
-
CHU de Nantes - Hôtel Dieu
Nantes, France
-
Centre Henri Becquerel
Rouen, France
-
Churchill Hospital
Oxford, United Kingdom
-
Cliniques Universitaires de Bruxelles - Hôpital Erasme
Brussels, Belgium
-
Hôpital Necker
Paris, France
-
Hôpital Saint-Louis
Paris, France
-
IUCT - Oncopole
Toulouse, France
-
Institut d'Hématologie de Basse Normandie
Caen, France
-
Medical University of Vienna
Vienna, Austria
-
Nottingham City Hospital
Nottingham, United Kingdom
-
The Christie
Manchester, United Kingdom
-
University College London Hospital
London, United Kingdom
-
University Hospital for Internal Medicine - University Hospital Graz
Graz, Austria
Conditions
Explore the condition pages connected to this study.